А. Revishvili, S. Golitsyn, S. Aksentiev, А. Amiraslanov, А. Artyukhina, D. Duplyakov, Е. Zubov, Е. Isaeva, А. Loginova, Т. Malkina, G. Miloserdov, А. Rivin, S. Teplykh, I. Tsygankova, Yu. Shvarts, Y. Yuricheva, S. Kanorsky, S. Sokolov
{"title":"阵发性心房颤动患者服用氢溴酸拉帕康尼汀缓释剂和普罗帕酮的比较研究","authors":"А. Revishvili, S. Golitsyn, S. Aksentiev, А. Amiraslanov, А. Artyukhina, D. Duplyakov, Е. Zubov, Е. Isaeva, А. Loginova, Т. Malkina, G. Miloserdov, А. Rivin, S. Teplykh, I. Tsygankova, Yu. Shvarts, Y. Yuricheva, S. Kanorsky, S. Sokolov","doi":"10.29296/25877305-2024-01-04","DOIUrl":null,"url":null,"abstract":"A new dosage form of lappaconitine hydrobromide has been created – the long-acting drug Allaforte®, which has fewer side effects compared to the traditional dosage form (Allapinin®).\nObjective. To evaluate the effectiveness, safety and tolerability of Allaforte® therapy in comparison with the drug Rytmonorm® in patients with paroxysmal atrial fibrillation (AF).\nMaterial and methods. Patients who met the inclusion criteria and those who did not meet the non-inclusion criteria were randomized into 2 groups: 1st (n=50) – \npatients received Allaforte® 25 mg 3 times a day with an increase in dose to \n50 mg 2 times a day when detected attack of AF; 2nd (n=50) – patients received Rytmonorm® 150 mg 3 times a day with an increase in dose to 300 mg 2 times a day if an attack of AF was detected.\nResults. The average time from the first dose of the drug to the development of AF paroxysm in the 1st group (Allaforte®) was 98.877±6.022 days, in the 2nd group (Rytmonorm®) – 98.808±5.876 days, the average time from the first dose of the drug to the completion of the study – 105.740±5.032 and 103.732±5.353 days, respectively. The drugs Allaforte® and Rytmonorm® equally improved the quality of life of patients. A comparative analysis in groups according to the severity of adverse events and their cause-and-effect relationship with the drug did not show significant differences.\nConclusion. The study drugs showed comparable effectiveness in preventing attacks of AF with similar safety and tolerability.","PeriodicalId":23748,"journal":{"name":"Vrach","volume":"52 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A comparative study of lappaconitine hydrobromide extended release and propafenone in patients with paroxysmal atrial fibrillation\",\"authors\":\"А. Revishvili, S. Golitsyn, S. Aksentiev, А. Amiraslanov, А. Artyukhina, D. Duplyakov, Е. Zubov, Е. Isaeva, А. Loginova, Т. Malkina, G. Miloserdov, А. Rivin, S. Teplykh, I. Tsygankova, Yu. Shvarts, Y. Yuricheva, S. Kanorsky, S. Sokolov\",\"doi\":\"10.29296/25877305-2024-01-04\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A new dosage form of lappaconitine hydrobromide has been created – the long-acting drug Allaforte®, which has fewer side effects compared to the traditional dosage form (Allapinin®).\\nObjective. To evaluate the effectiveness, safety and tolerability of Allaforte® therapy in comparison with the drug Rytmonorm® in patients with paroxysmal atrial fibrillation (AF).\\nMaterial and methods. Patients who met the inclusion criteria and those who did not meet the non-inclusion criteria were randomized into 2 groups: 1st (n=50) – \\npatients received Allaforte® 25 mg 3 times a day with an increase in dose to \\n50 mg 2 times a day when detected attack of AF; 2nd (n=50) – patients received Rytmonorm® 150 mg 3 times a day with an increase in dose to 300 mg 2 times a day if an attack of AF was detected.\\nResults. The average time from the first dose of the drug to the development of AF paroxysm in the 1st group (Allaforte®) was 98.877±6.022 days, in the 2nd group (Rytmonorm®) – 98.808±5.876 days, the average time from the first dose of the drug to the completion of the study – 105.740±5.032 and 103.732±5.353 days, respectively. The drugs Allaforte® and Rytmonorm® equally improved the quality of life of patients. A comparative analysis in groups according to the severity of adverse events and their cause-and-effect relationship with the drug did not show significant differences.\\nConclusion. The study drugs showed comparable effectiveness in preventing attacks of AF with similar safety and tolerability.\",\"PeriodicalId\":23748,\"journal\":{\"name\":\"Vrach\",\"volume\":\"52 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vrach\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29296/25877305-2024-01-04\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vrach","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29296/25877305-2024-01-04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A comparative study of lappaconitine hydrobromide extended release and propafenone in patients with paroxysmal atrial fibrillation
A new dosage form of lappaconitine hydrobromide has been created – the long-acting drug Allaforte®, which has fewer side effects compared to the traditional dosage form (Allapinin®).
Objective. To evaluate the effectiveness, safety and tolerability of Allaforte® therapy in comparison with the drug Rytmonorm® in patients with paroxysmal atrial fibrillation (AF).
Material and methods. Patients who met the inclusion criteria and those who did not meet the non-inclusion criteria were randomized into 2 groups: 1st (n=50) –
patients received Allaforte® 25 mg 3 times a day with an increase in dose to
50 mg 2 times a day when detected attack of AF; 2nd (n=50) – patients received Rytmonorm® 150 mg 3 times a day with an increase in dose to 300 mg 2 times a day if an attack of AF was detected.
Results. The average time from the first dose of the drug to the development of AF paroxysm in the 1st group (Allaforte®) was 98.877±6.022 days, in the 2nd group (Rytmonorm®) – 98.808±5.876 days, the average time from the first dose of the drug to the completion of the study – 105.740±5.032 and 103.732±5.353 days, respectively. The drugs Allaforte® and Rytmonorm® equally improved the quality of life of patients. A comparative analysis in groups according to the severity of adverse events and their cause-and-effect relationship with the drug did not show significant differences.
Conclusion. The study drugs showed comparable effectiveness in preventing attacks of AF with similar safety and tolerability.